Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Jazz Pharmaceuticals plc shares valued at $107,630 were purchased by COZADD BRUCE C on Jul 01 ’25. At $107.63 per share, COZADD BRUCE C acquired 1,000 shares.
Also, COZADD BRUCE C sold 500 shares, netting a total of over 55,000 in proceeds. Following the sale of shares at $110.00 each, the insider now holds 437,973 shares.
Before that, COZADD BRUCE C had sold 500 shares from its account. In a trade valued at $53,950, the Chairman & CEO traded Jazz Pharmaceuticals plc shares for $107.90 each. Upon closing the transaction, the insider’s holdings decreased to 500 shares, worth approximately $48.2 million.
As published in a research note from UBS on March 07, 2025, Jazz Pharmaceuticals plc [JAZZ] has been rated up from a Neutral to a Buy and the price target has been revised to $179 from $145. Analysts at Cantor Fitzgerald downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in late February. As of February 13, 2025, Wells Fargo has increased its “an Equal weight” rating to a “an Overweight” for JAZZ. Earlier on December 12, 2024, Morgan Stanley upgraded its rating. Their new recommendation was “an Overweight” for JAZZ stock which previously was a “an Equal-weight”.
Analyzing JAZZ Stock Performance
On last trading session,, Jazz Pharmaceuticals plc [NASDAQ: JAZZ] rose 0.44% to $109.92. The stock’s lowest price that day was $108.88, but it reached a high of $110.69 in the same session. During the last five days, there has been a surge of approximately 2.61%. Over the course of the year, Jazz Pharmaceuticals plc shares have jumped approximately 2.99%. Shares of the company reached a 52-week high of $148.06 on 02/26/25 and a 52-week low of $95.49 on 04/09/25.
Support And Resistance Levels for Jazz Pharmaceuticals plc (JAZZ)
According to the 24-hour chart, there is a support level at 108.97, which, if violated, would cause prices to drop to 108.02. In the upper region, resistance lies at 110.78. The next price resistance is at 111.64. RSI (Relative Strength Index) is 53.49 on the 14-day chart, showing neutral technical sentiment.
Is Jazz Pharmaceuticals plc subject to short interest?
Stocks of Jazz Pharmaceuticals plc saw a sharp steep in short interest on 2025-06-13 dropping by -0.12 million shares to 5.83 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 5.95 million shares. A decline of -2.11% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 6.58 of the overall float, the days-to-cover ratio (short ratio) decline to 6.58.
Which companies own the most shares of Jazz Pharmaceuticals plc (JAZZ)?
In terms of Jazz Pharmaceuticals plc share price expectations, FactSet research, analysts set an average price target of 215 in the next 12 months, up nearly 96.45% from the previous closing price of $109.44. Analysts anticipate Jazz Pharmaceuticals plc stock to reach 230 by 2025, with the lowest price target being 200. In spite of this, 6 analysts ranked Jazz Pharmaceuticals plc stock as Buy at the end of 2025. On June 05, 2024, Goldman assigned a price target of “a Buy” to the stock and initiated coverage with a $169.
